Eribulin in the Management of Advanced Breast Cancer: Implications of Current Research Findings.

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet (2011) 4.73

Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol (2008) 4.09

In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res (2001) 2.62

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol (2009) 2.05

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol (2010) 2.03

Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol (2015) 1.85

A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol (2011) 1.54

Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer (2010) 1.41

Marine-sourced anti-cancer and cancer pain control agents in clinical and late preclinical development. Mar Drugs (2014) 1.33

Isolation and structure of the cell growth inhibitory constituents from the western Pacific marine sponge Axinella sp. J Med Chem (1991) 1.32

Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology (2002) 1.15

Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer. Clin Breast Cancer (2014) 1.05

Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer. Breast Cancer Res Treat (2014) 1.05

A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Ann Oncol (1996) 0.97

Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer? Breast Cancer Res (2011) 0.94

Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment. Cancer Chemother Pharmacol (2012) 0.94

Eribulin mesylate. Clin Cancer Res (2011) 0.93

Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol (1994) 0.92

Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer. Oncologist (2014) 0.89

Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines. Springerplus (2014) 0.89

Advances in therapy: eribulin improves survival for metastatic breast cancer. Anticancer Drugs (2010) 0.83

Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells. Breast Cancer (2015) 0.83

Phase 1 combination study of eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer. Invest New Drugs (2014) 0.82

A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors. Invest New Drugs (2012) 0.81

Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer. Breast Cancer (Dove Med Press) (2011) 0.81

Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial. PLoS One (2013) 0.81

Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579). Breast Cancer Res Treat (2015) 0.79

Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9. Breast Cancer Res Treat (2015) 0.79

A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden. Acta Oncol (2014) 0.78

A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer. Br J Cancer (2015) 0.78

Anti-Cancer Products from Marine Sponges: Progress and Promise. Recent Pat Drug Deliv Formul (2015) 0.77

Retinal metastasis regression with eribulin in a heavily pretreated breast cancer patient. Future Oncol (2015) 0.76